Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02847429 |
Recruitment Status : Unknown
Verified January 2021 by Arog Pharmaceuticals, Inc..
Recruitment status was: Active, not recruiting
First Posted : July 28, 2016
Last Update Posted : January 22, 2021
|
Sponsor:
Arog Pharmaceuticals, Inc.
Collaborators:
Centre Leon Berard
Fox Chase Cancer Center
Information provided by (Responsible Party):
Arog Pharmaceuticals, Inc.
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet
publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending
Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during
QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review
assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific
validity or relevance of the submitted information.
Recruitment Status : | Unknown |
---|---|
Estimated Primary Completion Date : | August 2021 |
Estimated Study Completion Date : | August 2021 |
Submission Cycle | Results Submitted to ClinicalTrials.gov | Results Returned after Quality Control Review |
---|---|---|
1 |
January 30, 2024 | February 26, 2024 |